More data from the Phase III KEYNOTE-A18 study have been released, showing the potential for Merck & Co’s (NYSE: MRK) best-selling cancer drug to be used in earlier treatment settings.
The data relate to use of the PD-1 inhibitor Keytruda (pembrolizumab) for people who are newly diagnosed with high-risk and locally advanced cervical cancer.
Already available for use later on in the treatment of cervical cancer, Keytruda has picked up approvals across a broad range of cancers over the years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze